Skip to main content

Table 1 Demographic and clinical characteristics of the ACS patients by responsiveness to clopidogrel assessed by thromboelastography

From: High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study

 

Responders to clopidogrel (n = 732)

Nonresponders to clopidogrel (n = 289)

P value

Male, m (%)

601 (82.1%)

151 (52.2%)

0.000

Age, y

59.2 ± 10.3

62.9 ± 9.8

0.000

BMI, kg/m2

25.9 ± 3.2

25.6 ± 3.2

0.207

Medical history, n, (%)

 Diabetes mellitus

247 (33.7%)

113 (39.1%)

0.107

 Hypertension

463 (63.3%)

205 (70.9%)

0.020

 Previous stroke

74 (10.1%)

39 (13.5%)

0.120

 Previous myocardial infarction

55 (7.5%)

22 (7.6%)

0.957

 Previous CABG

3 (0.4%)

5 (1.7%)

0.045

 Previous PCI

53 (8.7%)

27 (6.6%)

0.236

Presentations of ACS

  

0.496

 Unstable angina

669 (91.4%)

258 (89.3%)

 

 Non-STEMI

32 (4.4%)

14 (4.8%)

 

 STEMI

31 (4.2%)

17 (5.9%)

 

Current or previous smoking, n (%)

440 (60.1%)

117 (40.5%)

0.000

Baseline laboratory evaluation

 PLT, × 109/L

210.5 ± 55.2

234.4 ± 62.1

0.000

 TC, mmol/L

3.8 ± 0.9

4.1 ± 1.0

0.000

 LDL-C, mmol/L

2.2 ± 0.7

2.4 ± 0.8

0.001

 HDL-C, mmol/L

1.0 ± 0.2

1.1 ± 0.3

0.002

 TGs, mmol/L

1.6 ± 1.0

1.5 ± 0.9

0.590

 Creatinine, μmol/L

72.0 ± 14.8

68.1 ± 17.2

0.000

Major medication administered in hospital

 ARBs, n, (%)

110 (15.0%)

40 (13.8%)

0.630

 ACEIs, n, (%)

161 (22.0%)

77 (26.2%)

0.113

 β-blockers, n, (%)

510 (69.7%)

209 (72.3%)

0.404

 CCBs, n, (%)

61 (8.3%)

21 (7.3%)

0.572

 Statins, n, (%)

715 (97.7%)

282 (97.6%)

0.925

 PPIs, n, (%)

369 (50.4%)

141 (48.8%)

0.641

Glucose indices

 Fasting glucose, mmol/L

6.2 ± 2.3

6.4 ± 2.0

0.154

 HbA1c, %

6.5 ± 1.3

6.3 ± 1.2

0.093

 Glycated albumin, %

15.6 ± 3.4

16.6 ± 3.6

0.000

 HOMA-IR

2.40 (1.65–3.77)

2.54 (1.71–3.95)

0.513

  1. BMI body mass index, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, non-STEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, PLT platelet count, TC total cholesterol, LDL-C low-density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, TGs triglycerides, ARBs angiotensin receptor blockers, ACEIs angiotensin-converting enzyme inhibitors, CCBs calcium channel blocking agents, PPIs proton pump inhibitor, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment for insulin resistance, calculated using the following formula: fasting serum insulin (μU/mL) * FPG (mmol/L)/156